biomarin pharmaceutical inc (BMRN) Key Developments
Biomarin Pharmaceutical Inc. Announces the Results of a Post-Hoc Sub-Analysis of the PKU-016 or ASCEND Study
Mar 30 15
BioMarin Pharmaceutical Inc. announced the results of a post-hoc sub-analysis of the PKU-016 or ASCEND study, the large randomized controlled trial evaluating neurocognitive outcomes in patients with phenylketonuria (PKU) treated with the approved therapy Kuvan® (sapropterin dihydrochloride) at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting. The sub-analysis included 86 subjects 8 to 17 years of age with PKU who were randomized to blinded treatment with Kuvan (N = 43) or placebo (N = 43) for 13 weeks, after which all individuals received open label Kuvan for an additional 13 weeks. This analysis evaluated the effects of Kuvan treatment on blood phenylalanine (Phe) concentration, attention deficit hyperactivity disorder like symptoms, and executive function defects in children and adolescents with PKU. Symptoms of ADHD were evaluated by using the attention deficit hyperactivity rating scale (ADHD-RS) commonly used to evaluate symptoms of inattentiveness and hyperactivity. There was a statistically significant difference between the baseline and week 13 ADHD-RS total score with Kuvan compared with placebo (p = 0.01). In addition to the total ADHD-RS score, the sub-analysis showed a statistically significant (p= 0.04) improvement in the inattention subscale score and statistically significance (p= 0.016) improvement in the hyperactivity subscale score for the Kuvan group compared with placebo from baseline to week 13.
Shire, AstraZeneca And Roche Show Interest In BioMarin
Mar 30 15
After several media outlets reported that Shire plc (LSE:SHP), AstraZeneca PLC (LSE:AZN) and Roche Holding AG (SWX:ROG) are considering buying BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), SunTrust says that it would be logical for several drug companies looking to build or expand their orphan disease franchises to buy BioMarin.
Shire Reportedly Looking To Buy BioMarin Pharma
Mar 27 15
There are market speculations that Shire plc (LSE:SHP) is considering acquiring BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) in a $65 billion deal. The shares of Shire rose today because of the merger speculations and UBS AG's confidence in Shire.
Myriad Genetics, Inc. Announces Expansion of Collaboration with BioMarin Pharmaceutical Inc
Mar 17 15
Myriad Genetics Inc. announced an expansion of the company's collaboration with BioMarin Pharmaceutical Inc. Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed. Talazoparib is an investigational poly-ADP ribose polymerase (PARP) inhibitor being developed by BioMarin. In the expanded relationship, the companies also will collaborate under FDA regulations and guidelines for the development and potential regulatory approval requirements for both talazoparib and myChoice HRD. The expansion adds to an ongoing collaboration that began in September 2013, when BioMarin began using Myriad's BRACAnalysis CDx companion diagnostic test in its pivotal Phase 3 EMBRACA and Phase 2 ABRAZO clinical studies of talazoparib for advanced or metastatic breast cancer patients carrying BRCA mutations.
AstraZeneca Reportedly Mulls Acquisition Of Biomarin Pharmaceuticals
Mar 12 15
AstraZeneca PLC (LSE:AZN) is reportedly seeking acquisition of BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN). “Pharmaceutical giant AstraZeneca (AZN) has been rumored to be interested in buying BioMarin for $175 per share in cash,” British newspaper Daily Mail reported